SCD1 inhibitor-3 is a safe, potent and orally active SCD1 inhibitor. SCD1 inhibitor-3 can be used for the research of metabolic diseases such as obesity, type II diabetes and dyslipidemia, as well as skin diseases, acne and cancer In Vivo SCD1 inhibitor-3 (compound 17a) (5 mg/kg; p.o.; 4 hours) reduces the plasma C16:1/C16:0 triglycerides desaturation index by 54 % . SCD1 inhibitor-3 (2~10 mg/kg; p.o.; 4 hours) makes a dose-responsive reduction of plasma triglycerides desaturation index . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Lewis rats Dosage: 5 mg/kg Administration: P.o.; 4 hours Result: Reduced the plasma C16:1/C16:0 triglycerides desaturation index by 54 %. Animal Model: Lewis rats Dosage: 2~10 mg/kg Administration: P.o.; 4 hours Result: A dose-responsive reduction of plasma triglycerides desaturation index. Form:Solid IC50& Target:SCD1